U.S. Markets closed

This Biotech Stock Grabbed A First In Depression — So What's Next?

ALLISON GATLIN
This Biotech Stock Grabbed A First In Depression — So What's Next?

Sage Therapeutics stock dipped Wednesday after the FDA approved its postpartum depression treatment, Zulresso. Investors are now looking at another depression drug called SAGE-217.